Delivery Order SPE2DB20D2104-SPE2DB25FMTKH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Potassium Chloride Extended Release 20 MEQ tablets in quantities of 1,000 units. This firm fixed-price delivery order, valued at $47,517.99, represents a non-competitive, non-set-aside award with an ultimate completion date of September 9, 2025. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Potassium Chloride Extended Release 20 MEQ tablets in quantities of 500 units, with a contract ceiling value of approximately $8,000. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on August 21, 2025, and will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $7,103.78 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Potassium Chloride Extended Release 10 MEQ tablets in quantities of 1,000 units. This competitively awarded, firm fixed price delivery order is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Potassium Chloride Extended Release 8 milliequivalent tablets in quantities of 500 units. This firm fixed price delivery order, valued at $6,588.65, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor agreement supporting global pharmaceutical procurement for military...
- The Defense Logistics Agency awarded a delivery order valued at $4,137.79 to AmerisourceBergen Drug Corp for 1,000 tablets of Potassium Chloride Extended Release 10 MEQ. This is a firm fixed-price, competitively awarded contract with a completion date of September 12, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,639.37 on August 14, 2025, for the supply of Potassium Chloride Extended Release 20 MEQ tablets in quantities of 500. This firm fixed-price, competitively awarded contract is scheduled for ultimate completion on August 15, 2025, with performance conducted at the vendor's corporate office in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating the award was made through...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for potassium chloride extended-release 8 milliequivalent tablets (500 count) on August 22, 2025, with a ceiling value of $1,543.91 and an ultimate completion date of August 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,178.58 to AmerisourceBergen Drug Corp for the supply of Potassium Chloride Extended Release 10 MEQ tablets in quantities of 1,000 units. This firm fixed-price delivery order, awarded on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a routine pharmaceutical procurement from the vendor's Conshohocken, Pennsylvania location. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $3,179.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 1,000 tablets of Potassium Chloride Extended Release 10 MEQ on July 30, 2025, with a completion date of July 31, 2025. This non-set-aside contract represents a routine pharmaceutical procurement executed through the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through...
- This federal contract award, valued at $8,208.54, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,568,077,879 units of Potassium Chloride Extended Release 20 MEQ Tablets in 500-count bottles. The contract has a period of performance through April 30, 2025 and is a firm fixed-price arrangement. Amerisourcebergen Drug Corp is the prime contractor, and...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMTKHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Potassium Chloride Extended Release 8 MEQ tablets (500-count packages) with a ceiling value of $4,774.04. This is a firm fixed-price delivery order with an ultimate completion date of June 17, 2025, and represents a non-competitive set-aside award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999 prime vendor agreement running through December 2026 that serves as the primary pharmaceutical support vehicle for federal military healthcare systems worldwide. AmerisourceBergen is a major pharmaceutical distributor that supplies a comprehensive range of medications and medical supplies to support Defense Health Agency operations, the U.S. Coast Guard, and other government healthcare entities. The company's federal contract portfolio demonstrates extensive capability in delivering specialty medications, generic drugs, and medical commodities across multiple therapeutic domains to meet military healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 6/16/25 |